SCHEMBL23458178

SCHEMBL23458178

CC(C)(C)OC(=O)N1CCOCC1C(N)=S

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
USP2 O75604 1/20 0.46
RECQL P46063 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.37
LMNA P02545 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
NR1H2 P55055 1/20 0.35
SCN5A Q14524 1/20 0.34
SCN3A Q9NY46 1/20 0.34
IL1B P01584 1/20 0.34
P2RX7 Q99572 1/20 0.34
PDK1 Q15118 2/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
SCN4A P35499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16604796 0.88 SMN1; SMN2 (0.49) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL16604806 0.88 SMN1; SMN2 (0.49) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL3511572 0.88 SMN1; SMN2 (0.49) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL6466005 0.85 SMN1; SMN2 (0.38) SMN1; SMN2USP2RECQLHSD17B10NPC1
SCHEMBL15746865 0.84 SMN1; SMN2 (0.45) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL24716881 0.84 SMN1; SMN2 (0.45) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL24716617 0.84 SMN1; SMN2 (0.45) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL2737895 0.84 SMN1; SMN2 (0.47) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL15561495 0.84 SMN1; SMN2 (0.47) SMN1; SMN2USP2RECQLCA12CA1
SCHEMBL5475967 0.84 SMN1; SMN2 (0.47) SMN1; SMN2USP2RECQLCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114746419-B N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors 国家医疗保健研究所 2023-10-24 CN disclosed
US-20230036867-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2023-02-02 US disclosed
EP-4069692-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2022-10-12 EP disclosed
CN-114746419-A N- (3- (5- (pyrimidin-4-yl) thiazol-4-yl) phenyl) sulfonamide compounds and their use as BRAF inhibitors 国家医疗保健研究所 2022-07-12 CN disclosed
WO-2021110997-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230036867-A1 N-(3-(5-(PYRIMIDIN-4-YL)THIAZOL-4-YL)PHENYL)SULFONAMIDE COMPOUNDS AND THEIR USES AS BRAF INHIBITORS BRAF, RAF1, NRAS SMN1; SMN2 2600/4885USP2 2857/4885RECQL 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.